Bio-Repository

 

The Vancouver Prostate Centre has a tumour bank that contains well over 2000 prostate cancer specimens (both fresh frozen and paraffin embedded). This tumour bank has an integrated database that is overseen by a full-time coordinator, along with a full-time research pathologist and staff.

Resources

The Vancouver Prostate Centre’s collection includes the world’s largest repository of the following:

  • pre- and post-treated prostate cancers
  • tumours stratified from low to high risk (matched primary and metastatic tumours)
  • treatment resistant cancers fully annotated for previous therapies, responses, stage, and prognostic indicators, biomarkers etc.

An established bank of more than 700 human radical prostatectomy specimens stored at -156 degrees centigrade and in paraffin blocks

More than 1,000 archived prostatectomy specimens from patients with no prior hormone therapy or after variable periods of pre-treatment with one, three, or eight months of neo-adjuvant hormone therapy prior to surgery.

The VPC has also constructed the following:

  • Tissue microarrays (TMAs) from post-treated cancer specimens that are useful for high throughput validation of transcriptional profiles.
  • TMAs spotted with control normal prostate tissue together with more than 400 individual samples from benign, PIN, and Gleason grades of 3, 4, and 5 all linked to clinical correlative data and PSA recurrence rate status.
  • A unique post-hormone therapy treated TMA consisting of a total of 336 cores from 112 patients treated with no hormone therapy (21), 3-6 (49), and more than 8 (28) months of neo-adjuvant hormone therapy prior to radical prostatectomy, and 14 patients with metastatic castrate resistant prostate cancer.
  • TMAs from patients entered into the Canadian Uro-Oncology Group randomized comparative study of 3 vs 8 months of neo-adjuvant hormone therapy, as well as from a multicentre Phase II trial of 70 patients treated with neo-adjuvant hormone plus docetaxel, all with annotated clinical and pathological correlates.
  • TMA of 14 metastatic lymph node lesions paired with biopsies from the primary lesion. Approximately half of these lesions have been pre-treated with androgen ablation therapy, and all have clinical correlative and follow up data.

Background

The Vancouver Prostate Centre has been collecting human prostate tissue from patients undergoing radical prostatectomy for well over 15 years. The process of collecting and bio-banking these specimens has been undertaken with an institutionally approved consent form and each individual specimen has been consented for research purposes within the institution. VPC implements high ethical standards to protect patient’s confidentiality in this process.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Plaid for Dad

Plaid for Dad Fundraiser, June 14, 2019

Plaid for Dad is a workplace fundraiser for Prostate Cancer Canada, with online registration & fundraising leading up to Friday June 14th's "wear plaid to work" day. Visit the event website to register a team, join/fundraise for a team or buy plaid to wear on the day.      

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC takes place on Sunday June 16, 2019 in various locations across BC. Registration fees ($40) include a shirt and BBQ lunch, and are waived for those who raise over $150. Click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Friday, May 3, 2019

Dr. Mads Daugaard receives the St. Baldrick’s Foundation Robert J. Arceci Innovation Award

Dr. Daugaard
Thursday, April 18, 2019

Dr. Subramaniam joins UBC as Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design

Dr. Subramaniam
Monday, April 1, 2019

VPC's translational research profiled in UBC Faculty of Medicine News

Dr. Gleave at the VPC